- βBoth insulin pumps and MDI achieved similar blood sugar control during pregnancy when CGM was used
- βMaternal and infant outcomes including breastfeeding were similar at 1 and 3 months post-delivery
- βStudy provides reassurance that MDI is a viable and effective option during T1D pregnancy
| Journal | Acta diabetologica |
| Year | 2026 |
| PMID | 40759795 |
What This Study Looked At
Researchers examined whether using an insulin pump (versus multiple daily injections, or MDI) made a difference in pregnancy outcomes for women with type 1 diabetes (T1D). All 141 women in the study used continuous glucose monitoring (CGM) throughout their pregnancies.
Key Findings
Both groups β 39 women using non-automated insulin pumps and 102 using MDI β achieved remarkably similar blood sugar control throughout pregnancy. HbA1c levels and average sensor glucose readings were nearly identical between the two groups from early to late pregnancy.
However, there were some notable differences in delivery outcomes:
- Preterm birth (before 37 weeks) was more common in pump users (26% vs. 17%)
- Caesarean section rates were higher in pump users (59% vs. 40%)
- These differences held even after accounting for age, diabetes duration, and complications
After Delivery
At 1 and 3 months after giving birth, outcomes for both mothers and babies β including breastfeeding rates β were similar between the two groups. Pump users required insulin dose adjustments during pregnancy (higher basal rates, adjusted carb ratios), which largely returned to pre-pregnancy levels after delivery.
What This Means for You
If you have type 1 diabetes and are pregnant or planning a pregnancy, this study suggests that with good CGM use, MDI can be just as effective as an insulin pump for blood sugar control. The higher rates of preterm birth and C-section in pump users were unexpected and warrant further investigation. Talk to your diabetes care team about which insulin delivery method is right for your individual situation.
